{
  "ticker": "ATH",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972291",
  "id": "02972291",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250724",
  "time": "1008",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m36br4dtw2w9.pdf",
  "summary": "- **Peer-reviewed publication** of novel **MSA Atrophy Index (MSA-AI)**, a neuroimaging tool for diagnosing/tracking **Multiple System Atrophy (MSA)** progression.  \n- **Clinical relevance**: MSA-AI correlates with disease severity (\u03c1=\u22120.57, p<0.001) and predicts progression (\u03c1=\u22120.55, p=0.035).  \n- **Potential impact**: Supports **patient selection** and **disease monitoring** in Alterity\u2019s **Phase 2/3 clinical trials** for MSA.  \n\nNo explicit capital markets or trading implications (e.g., funding, timelines, partnerships) identified. Focus is on scientific validation.  \n\n*Note: Omitted operational/background details per prompt.*",
  "usage": {
    "prompt_tokens": 2387,
    "completion_tokens": 158,
    "total_tokens": 2545,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T01:04:48.329950"
}